A Hidden Treasure From the Russian Revolution Was Just DiscoveredConstruction in Torzhok unearthed a remarkable hoard of 409 gold coins, dating from 1848 to 1911, hidden in a ceramic mug. Experts believe ...
One Night at the Adlon in BerlinAs India seeks to get closer to Europe for strategic and cultural reasons, it is nice to find the PM having spent some time under the linde...
Russia hosts first royal wedding a century after Bolshevik revolution as Romanov heir ties the knot with Italian fiancéeGrand Duke George Mikhailovich Romanov and Rebecca Virginia Bettarini took their vows at Saint Isaac's cathedral.
Top 10 things to do in the blissful shores of Azores islandsThere are more than 200 endemic and migratory species, such as the Azores bullfinch and grey wagtail, the region is very popular with birdw...
- Paths of exile
We know this from two more important exiles, one from thousands of years ago and the other contemporary.
- UPA-II could meet the fate of European ruling parties: CPI(M)
CPI(M) today warned that UPA-II could meet the fate of several European ruling parties which recently suffered electoral defeat.
- Drug companies plan late-stage deals with MNCs
In a distinct shift in their new drug development strategy, Indian pharma majors such as Dr Reddy’s Lab (DRL), Nicholas Piramal, Wockhardt ...
- NPIL, Merck in research deal for cancer drugs
Nicholas Piramal (NPIL) has signed a research deal potentially worth a maximum revenue of $350 million with US pharmaceutical giant Merck &...
- Nicholas Piramal to take oncology drug overseas alone
Nicholas Piramal plans to take up oncology market on its own for its anti-blood cancer drug.
- Nicholas's NCE pipeline at Rs 1000-1300 cr: Emkay
Emkay Research is positive on the developments and business of Nicholas Piramal Ltd though it has not made any formal rating on the stock.
- NP to conduct clinical trial in US for cancer drug
Nicholas Piramal to conduct this trial for the first time in the US for its breakthrough blood cancer drug.
- Nicholas Piramal gets FDA okay for cancer drug trials
Nicholas Piramal announced on Monday that it had received approval from the USFDA to start clinical trials on humans for its new cancer dru...
- Top pharma cos hike R&D spend, ramp up portfolio
India’s top pharma companies are dramatically increasing their R&D spending, as they ramp up product pipelines abroad and their new researc...
- PE cos eye Nicholas Piramal's R&D unit
Private equity funds, including DE Shaw, Temasek Holdings and HBM Partners, are believed to have approached Nicholas Piramal to fund the ph...
- Ranbaxy's pact with GSK gives it scope for drug devt
Ranbaxy Labs had earlier entered into an agreement with GlaxoSmithKline, under which the domestic pharma major was responsible for selectin...
- Indian pharma cos close to blockbuster breakthrough
Indian pharma majors may manage to market their first indi-genous "blockbuster drugs" or new chemical entities (NCEs) in the next four year...
- NPIL reshuffles top deck
Nicholas Piramal’s recent acquisition of Pfizer’s UK facility has not suppressed its appetite for more inorganic growth.